BELLEROPHON THERAPEUTICS INC (BLPH) Stock Price, Quote, News and Overview
NASDAQ:BLPH - Nasdaq - US0787713009 - Common Stock - Currency: USD
BLPH Quote, Performance and Key Statistics
0.1025
-0.28 (-73.39%)
The current stock price of BLPH is 0.1025 USD. In the past month the price decreased by -75.43%. In the past year, price decreased by -90.05%.
BLPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BLPH
Company Profile
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. The company is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Company Info
BELLEROPHON THERAPEUTICS INC
184 Liberty Corner Road, Suite 302
WARREN NEW JERSEY 07059 US
CEO: Fabian Tenenbaum
Employees: 18
Company Website: http://www.bellerophon.com/
Phone: 19085744770.0
BELLEROPHON THERAPEUTICS INC / BLPH FAQ
What is the stock price of BELLEROPHON THERAPEUTICS INC today?
The current stock price of BLPH is 0.1025 USD. The price decreased by -73.39% in the last trading session.
What is the ticker symbol for BELLEROPHON THERAPEUTICS INC stock?
The exchange symbol of BELLEROPHON THERAPEUTICS INC is BLPH and it is listed on the Nasdaq exchange.
On which exchange is BLPH stock listed?
BLPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BELLEROPHON THERAPEUTICS INC stock?
6 analysts have analysed BLPH and the average price target is 2.04 USD. This implies a price increase of 1890.24% is expected in the next year compared to the current price of 0.1025. Check the BELLEROPHON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BELLEROPHON THERAPEUTICS INC worth?
BELLEROPHON THERAPEUTICS INC (BLPH) has a market capitalization of 1.25M USD. This makes BLPH a Nano Cap stock.
How many employees does BELLEROPHON THERAPEUTICS INC have?
BELLEROPHON THERAPEUTICS INC (BLPH) currently has 18 employees.
Should I buy BELLEROPHON THERAPEUTICS INC (BLPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLPH, evaluating the profitability, health, valuation and growth aspects
- BELLEROPHON THERAPEUTICS INC (BLPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BELLEROPHON THERAPEUTICS INC (BLPH) Sales and EPS estimates to see what analysts future expectations are.
- BELLEROPHON THERAPEUTICS INC (BLPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BELLEROPHON THERAPEUTICS INC (BLPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- BELLEROPHON THERAPEUTICS INC (BLPH) Stock Chart to make your own analysis
- BELLEROPHON THERAPEUTICS INC (BLPH) Latest news and press-releases to stay up to date.
Does BELLEROPHON THERAPEUTICS INC (BLPH) stock pay dividends?
BLPH does not pay a dividend.
When does BELLEROPHON THERAPEUTICS INC (BLPH) report earnings?
BELLEROPHON THERAPEUTICS INC (BLPH) will report earnings on 2023-11-13, before the market open.
What is the Price/Earnings (PE) ratio of BELLEROPHON THERAPEUTICS INC (BLPH)?
BELLEROPHON THERAPEUTICS INC (BLPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
BLPH Technical Analysis
BLPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BLPH. While BLPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
BLPH Financial Highlights
Over the last trailing twelve months BLPH reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 38.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.28% | ||
| ROE | -220.54% | ||
| Debt/Equity | 0 |
BLPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BLPH. The Buy consensus is the average rating of analysts ratings from 6 analysts.